OIPE
FEB 11 2008
PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Attorney Docket No.: 18184-0004-00-US	Serial No.: 10/728,261
	Applicants Herbert W. HARRIS *et al.*	Page 1 of 1
PTO Form 1449	Filing Date: December 3, 2003	Group Art Unit: 1617

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
		RE 30,014	05-29-1979	Korosi *et al.*			
		4,025,528	05-1977	Maeda *et al.*			
		5,457,118	10-1995	Dickinson *et al.*			
		6,291,530	09-2001	Greenspan *et al.*			
		6,683,072	01-27-2004	Kucharik *et al.*			
		2004/0138209	07-15-2004	Kucharik *et al.*			
		2004/0138210	07-15-2004	Harris *et al.*			
		2004/0157833	08-12-2004	Harris *et al.*			
		2004/0162284	08-19-2004	Harris *et al.*			
		2004/0224943	11-11-2004	Leventer *et al.*			
		2004/0229866	11-18-2004	Harris *et al.*			
		2004/0254173	12-16-2004	Leventer *et al.*			
		2005/0075329	04-07-2005	Leventer *et al.*			
		2005/0288277	12-29-2005	Kucharik *et al.*			
		2007/0032479	02-08-2007	Leventer *et al.*			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation YES	NO
		02/094189	11-28-2002	WO				
		00/24400	05-04-2000	WO				
		492 485	07-01-1992	EP			**Abstract**	
		92/11262	07-09-1992	WO			**Abstract**	
		178519	03-31-1983	HU			**X**	

OTHER DOCUMENTS

(Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KC/

OIPE IAP9 FEB 11 2008 PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION	Attorney Docket No.: 18184-0004-00-US	Serial No.: 10/728,261
(Use several sheets if necessary)	Applicants Herbert W. HARRIS *et al.*	Page 1 of 1
PTO Form 1449	Filing Date: December 3, 2003	Group Art Unit: 1617

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation YES	Translation NO

OTHER DOCUMENTS

(Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s).)

		CA97:6331(Toke), 1982.
		Y. ADACHI *et al.*, "Use of tofisopam (Grandaxin®) in autonomic imbalance and irritable bowel syndrome", *Igaku to Yakugaku,* **1987**, 18(5), 1591-94, Japan. (Translation provided.)
		T. AOYAGI *et al.*, Yakuri to Chiryo, "Clinical evaluation of tofisopam (grandaxin®) in various unidentified gastrointestinal complaints", **1992**, *20*(2), 295-305, Japan. (Translation provided.)
		S. ASANO *et al.*, "Study of the efficacy and safety of grandaxin tablets in vague complaints associated with gastrointestinal conditions", *Shinyaku to Rinsho*, **1993**, *42*(12), 95-100, Japan. (Translation provided.)
		V.S. CHADWICK, *et al.*, "Activation of the mucosal immune system in irritable bowel syndrome", *Gastroenterology*, **2002**, *122*(7), 1778-83.
		S.M. COLLINS, *et al.*, "The putative role of inflammation in the irritable bowel syndrome", *Gut*, **2001**, *49*(6), 743-45.
		M. CSILLAG *et al.*, "The treatment of climacteric syndrome with tofizopam (grandaxin)", *Ther Hung*, **1975**, *23*(4), 164-69.
		F. GALDIERO, *et al.*, "Effects of Benzodiazepines on Immunodeficiency and Resistance in Mice", *Life Sciences*, Vol. 57. No. 26, pp. 2413-2423, 1995
		A. KATO *et al.*, "Clinical report on grandaxin for various unidentified complaints", *Yakuri to Chiryo*, **1987**, *15*(8), 163-71, Japan. (Translation provided.)
		S. KISHIMOTO *et al.*, "Clinical effect of grandaxin on dyspeptic patients", *Yakuri to Chiryo*, **1989**, *17*(5): 457-64, Japan. (Translation provided.)
		A. KITANO *et al.*, "Clinical effect of tofisopam (grandaxin®) on vague gastrointestinal complaints", *Shinyaku to Rinsho*, **1988**, *37*(9), 169-73, Japan. (Translation provided.)
		M. KOJIMA, *et al.*, "Effects of Tofisopam on Lower Digestive Tract Dysfunction", *Clinical Report*, **1996**, *30*(5), 989-94. (Translation provided.)

Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KC/

INFORMATION DISCLOSURE CITATION	Attorney Docket No.: 18184-0004-00-US	Serial No.: 10/728,261
(Use several sheets if necessary)	Applicants Herbert W. HARRIS *et al.*	Page 1 of 1
PTO Form 1449	Filing Date: December 3, 2003	Group Art Unit: 1617

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	**Translation** **YES**	**NO**

OTHER DOCUMENTS

(Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s).)

		Y. MATSUO, et al., "Effect of Tofisopam on Experimental Ulcers", *Yakuri to Chiryo*, **1998**, 16(8), 157-64. (Translation provided.)
		M. OSIPENKO *et al.*, "Role of grandaxin in the treatment of functional diseases of the gastrointestinal tract.", *Terapevt. Arkhiv*, **2000**, *10*, 23-27. (Translation provided.)
		O. OYESANMI, *et al.*, "Hematologic Side Effects of Psychotropics", *Psychosomatics*, ~~199~~ 1999, 40(5), 414-21.
		J. RISTELHUEBER *et al.*, "Utility of a new anxiolytic, tofisopam, in current gastroenterology practice," *Revue Francaise de Gastro-Enterologie*, **1977**, *125*, 49-52, France. (Translation provided.)
		J. SZEGÓ *et al.*, "Selected passages from the clinical-pharmacological and clinical trials of grandaxin", *Acta Pharm. Hung.*, **1993**, *63*, 91-98, Hungary. (Translation provided.)
		H. TAKADA *et al.*, "Clinical study of grandaxin for unidentified complaints", *Yakuri to Chiryo*, **1989**, *17*(3), 381-92, Japan. (Translation provided.)
		K. YOSHIKAWA *et al.*, "Clinical evaluation of grandaxin® (tofisopam) on several skin diseases," *Hifu*, **1993**, *35*(1), 195-202, Japan. (Translation provided.)

Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KC/

OIPE
FEB 11 2008
PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Attorney Docket No.: 18184-0004-00-US	Serial No.: 10/728,261
	Applicants Herbert W. HARRIS *et al.*	Page 1 of 1
PTO Form 1449	Filing Date: December 3, 2003	Group Art Unit: 1617

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
		RE 30,014	05-29-1979	Korosi *et al.*			
		4,025,528	05-1977	Maeda *et al.*			
		5,457,118	10-1995	Dickinson *et al.*			
		6,291,530	09-2001	Greenspan *et al.*			
		6,683,072	01-27-2004	Kucharik *et al.*			
		2004/0138209	07-15-2004	Kucharik *et al.*			
		2004/0138210	07-15-2004	Harris *et al.*			
		2004/0157833	08-12-2004	Harris *et al.*			
		2004/0162284	08-19-2004	Harris *et al.*			
		2004/0224943	11-11-2004	Leventer *et al.*			
		2004/0229866	11-18-2004	Harris *et al.*			
		2004/0254173	12-16-2004	Leventer *et al.*			
		2005/0075329	04-07-2005	Leventer *et al.*			
		2005/0288277	12-29-2005	Kucharik *et al.*			
		2007/0032479	02-08-2007	Leventer *et al.*			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation YES	NO
		02/094189	11-28-2002	WO				
		00/24400	05-04-2000	WO				
		492 485	07-01-1992	EP			**Abstract**	
		92/11262	07-09-1992	WO			**Abstract**	
		178519	03-31-1983	HU			**X**	

OTHER DOCUMENTS

(Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KC/

INFORMATION DISCLOSURE CITATION	Attorney Docket No.: 18184-0004-00-US	Serial No.: 10/728,261
(Use several sheets if necessary)	Applicants Herbert W. HARRIS *et al.*	Page 1 of 1
PTO Form 1449	Filing Date: December 3, 2003	Group Art Unit: 1617

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation YES	NO

OTHER DOCUMENTS

(Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s).)

		CA97:6331(Toke), 1982.
		Y. ADACHI *et al.*, "Use of tofisopam (Grandaxin®) in autonomic imbalance and irritable bowel syndrome", *Igaku to Yakugaku*, **1987**, 18(5), 1591-94, Japan. (Translation provided.)
		T. AOYAGI *et al.*, Yakuri to Chiryo, "Clinical evaluation of tofisopam (grandaxin®) in various unidentified gastrointestinal complaints", **1992**, *20*(2), 295-305, Japan. (Translation provided.)
		S. ASANO *et al.*, "Study of the efficacy and safety of grandaxin tablets in vague complaints associated with gastrointestinal conditions", *Shinyaku to Rinsho*, **1993**, *42*(12), 95-100, Japan. (Translation provided.)
		V.S. CHADWICK, *et al.*, "Activation of the mucosal immune system in irritable bowel syndrome", *Gastroenterology*, **2002**, *122*(7), 1778-83.
		S.M. COLLINS, *et al.*, "The putative role of inflammation in the irritable bowel syndrome", *Gut*, **2001**, *49*(6), 743-45.
		M. CSILLAG *et al.*, "The treatment of climacteric syndrome with tofizopam (grandaxin)", *Ther Hung*, **1975**, *23*(4), 164-69.
		F. GALDIERO, *et al.*, "Effects of Benzodiazepines on Immunodeficiency and Resistance in Mice", *Life Sciences*, Vol. 57. No. 26, pp. 2413-2423, 1995
		A. KATO *et al.*, "Clinical report on grandaxin for various unidentified complaints", *Yakuri to Chiryo*, **1987**, *15*(8), 163-71, Japan. (Translation provided.)
		S. KISHIMOTO *et al.*, "Clinical effect of grandaxin on dyspeptic patients", *Yakuri to Chiryo*, **1989**, *17*(5): 457-64, Japan. (Translation provided.)
		A. KITANO *et al.*, "Clinical effect of tofisopam (grandaxin®) on vague gastrointestinal complaints", *Shinyaku to Rinsho*, **1988**, *37*(9), 169-73, Japan. (Translation provided.)
		M. KOJIMA, *et al.*, "Effects of Tofisopam on Lower Digestive Tract Dysfunction", *Clinical Report*, **1996**, *30*(5), 989-94. (Translation provided.)

Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KC/

PTO
IAP9
FEB 11 2008
PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION	Attorney Docket No.: 18184-0004-00-US	Serial No.: 10/728,261
(Use several sheets if necessary)	Applicants Herbert W. HARRIS *et al.*	Page 1 of 1
PTO Form 1449	Filing Date: December 3, 2003	Group Art Unit: 1617

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation YES	NO

OTHER DOCUMENTS

(Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s).)

		Y. MATSUO, et al., "Effect of Tofisopam on Experimental Ulcers", *Yakuri to Chiryo*, **1998**, 16(8), 157-64. (Translation provided.)
		M. OSIPENKO *et al.*, "Role of grandaxin in the treatment of functional diseases of the gastrointestinal tract.", *Terapevt. Arkhiv*, **2000**, *10*, 23-27. (Translation provided.)
		O. OYESANMI, *et al.*, "Hematologic Side Effects of Psychotropics", *Psychosomatics*, 199, 40(5), 414-21.
		J. RISTELHUEBER *et al.*, "Utility of a new anxiolytic, tofisopam, in current gastroenterology practice," *Revue Francaise de Gastro-Enterologie*, **1977**, *125*, 49-52, France. (Translation provided.)
		J. SZEGÓ *et al.*, "Selected passages from the clinical-pharmacological and clinical trials of grandaxin", *Acta Pharm. Hung.*, **1993**, *63*, 91-98, Hungary. (Translation provided.)
		H. TAKADA *et al.*, "Clinical study of grandaxin for unidentified complaints", *Yakuri to Chiryo*, **1989**, *17*(3), 381-92, Japan. (Translation provided.)
		K. YOSHIKAWA *et al.*, "Clinical evaluation of grandaxin® (tofisopam) on several skin diseases," *Hifu*, **1993**, *35*(1), 195-202, Japan. (Translation provided.)

Examiner	/Kendra Carter/	Date Considered	04/23/2008

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KC/